Research suggests that MGMT genomic rearrangements may contribute to chemotherapy resistance in gliomas. Various studies are exploring different aspects of glioma treatment, including the use of vaccine therapies, radiogenomic classification, and the role of epigenetic mechanisms. The relationship between these factors and chemotherapy resistance is being investigated, with potential implications for personalized treatment and diagnosis of glioblastoma patients.